Morgan Stanley Y M Abs Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 292,567 shares of YMAB stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

292,567

Previous 500,161 41.51%

Holding current value

$2.49 Million

Previous $2.22 Million 40.45%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$3.64 - $5.35 $755,642 - $1.11 Million	-207,594 Reduced 41.51%	292,567 $1.32 Million
Q1 2025 May 15, 2025	BUY	$4.43 - $8.17 $794,538 - $1.47 Million	179,354 Added 55.91%	500,161 $2.22 Million
Q4 2024 Feb 14, 2025	BUY	$7.76 - $15.69 $559,379 - $1.13 Million	72,085 Added 28.98%	320,807 $2.51 Million
Q3 2024 May 14, 2025	BUY	$9.95 - $15.39 $453,540 - $701,506	45,582 Added 22.44%	248,722 $3.27 Million
Q3 2024 Nov 14, 2024	BUY	$9.95 - $15.39 $453,540 - $701,506	45,582 Added 22.44%	248,722 $3.27 Million
Q2 2024 May 14, 2025	SELL	$11.6 - $17.25 $1.36 Million - $2.03 Million	-117,667 Reduced 36.68%	203,140 $2.45 Million
Q2 2024 Oct 17, 2024	BUY	$11.6 - $17.25 $174,498 - $259,491	15,043 Added 8.0%	203,140 $2.45 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.25 $174,498 - $259,491	15,043 Added 8.0%	203,140 $2.45 Million
Q1 2024 Oct 17, 2024	SELL	$6.57 - $18.69 $98,832 - $281,153	-15,043 Reduced 7.41%	188,097 $3.06 Million
Q1 2024 Aug 16, 2024	SELL	$6.57 - $18.69 $374,805 - $1.07 Million	-57,048 Reduced 23.27%	188,097 $3.06 Million
Q1 2024 May 15, 2024	SELL	$6.57 - $18.69 $374,805 - $1.07 Million	-57,048 Reduced 23.27%	188,097 $3.06 Million
Q4 2023 Aug 16, 2024	BUY	$4.88 - $7.42 $204,984 - $311,677	42,005 Added 20.68%	245,145 $1.67 Million
Q4 2023 Feb 13, 2024	BUY	$4.88 - $7.42 $669,882 - $1.02 Million	137,271 Added 127.25%	245,145 $1.67 Million
Q3 2023 Nov 15, 2023	SELL	$4.86 - $7.23 $110,555 - $164,468	-22,748 Reduced 17.42%	107,874 $587,000
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $680,617 - $1.24 Million	-119,827 Reduced 47.84%	130,622 $886,000
Q1 2023 May 15, 2023	SELL	$2.83 - $5.11 $123,144 - $222,356	-43,514 Reduced 14.8%	250,449 $1.25 Million
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $115,413 - $583,605	38,471 Added 15.06%	293,963 $1.43 Million
Q3 2022 Nov 14, 2022	SELL	$13.96 - $19.67 $1.66 Million - $2.33 Million	-118,664 Reduced 31.72%	255,492 $3.68 Million
Q2 2022 Oct 27, 2022	SELL	$8.22 - $15.13 $1.38 Million - $2.53 Million	-167,405 Reduced 30.91%	374,156 $5.66 Million
Q2 2022 Aug 15, 2022	SELL	$8.22 - $15.13 $1.38 Million - $2.53 Million	-167,405 Reduced 30.91%	374,156 $5.66 Million
Q1 2022 Oct 27, 2022	BUY	$6.55 - $17.42 $1.1 Million - $2.92 Million	167,405 Added 44.74%	541,561 $6.43 Million
Q1 2022 May 13, 2022	BUY	$6.55 - $17.42 $1.65 Million - $4.38 Million	251,177 Added 86.5%	541,561 $6.43 Million
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $3.2 Million - $6.05 Million	206,378 Added 245.67%	290,384 $4.71 Million
Q3 2021 Nov 15, 2021	BUY	$27.47 - $37.31 $2.31 Million - $3.13 Million	84,006 New	84,006 $2.4 Million

Others Institutions Holding YMAB

# of Institutions

Shares Held

26M

Call Options Held

24K

Put Options Held

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $372M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account